Inspra Helps, Natrecor Useless for Heart Patients
By wchung | 21 Mar, 2026
There’s good news for millions of people with mild or moderate heart failure. Studies show that the Pfizer drug Inspra and an implanted device from Medtronic can boost survival and cut down on trips to the hospital.
However, another drug that has been used for nearly a decade, Johnson & Johnson’s Natrecor (NAY’-treh-kor), did little to help people with severe heart failure in a study aimed at resolving safety concerns. Doctors say the drug seems safe but does not markedly help shortness of breath or save lives.
The studies were presented Sunday at an American Heart Association conference in Chicago.
MARILYNN MARCHIONE, AP Medical Writer CHICAGO
Articles
- Airports Step up to Feed Unpaid TSA Workers
- Don Struggles for a Face-Saving Exit from a Self-Created Nightmare
- OpenAI to Double Workforce to 8,000 by End of 2026
- BTS Comeback Concert Shuts Down Central Seoul
- United Cuts 5% of Flights, Plans for $175 per Barrel Oil
- Softbank, AEP to Build Massive Ohio Gas Power Plant, Data Center
- Musk's Liable to Twitter Shareholders, Damages to Be Determined
- Next-Gen Parenting for Success in an Automating World—for Yourself and Your Kids
- MLB’s Opening Day Odds and Value Picks
- Attack on Harvard Renewed with Another Antisemitism Suit